New inhaled drug HSK39004 shows promise for COPD in early trial

NCT ID NCT07331402

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests an inhaled drug called HSK39004 in 12 people with COPD. The study measures how much drug gets into the blood and how it affects lung function over 12 hours. It compares HSK39004 to an existing treatment to see if it works as well or better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HSK39004 inhalation suspension (also known as Ohtuvayre)

What this could lead to

If successful, this could lead to a new inhaled treatment option for COPD that helps improve lung function.

What could go wrong

This is a small, early Phase 2 trial with only 12 participants, so results may not apply to all COPD patients. The drug is still being tested for safety and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • 36 Sanhao Street, Heping District, Shenyang, Liaoning,China

    Shenyang, Liaoning, China